Aptus Pharma H1 FY27 Net Profit Rs. 507.66 Lacs, Revenue Rs. 489.20 Lacs
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 20 Oct 2026, 07:29 PM IST · BSE ID: a28a4742-4fe1-4f72-9553-0f9c3d98d83a
View Original BSE Filing (PDF)
💡
In Simple Terms
Aptus Pharma announced its half-year earnings, showing increased profit and revenue, with plans for new share issuance.
🤖 AI Summary
- Aptus Pharma Limited reported Net Profit of Rs. 507.66 Lacs for the half year ended September 30, 2026.
- Revenue from Operations for the half year stood at Rs. 489.20 Lacs.
- Basic Earnings Per Share (EPS) for the half year was Rs. 2.96, adjusted for a bonus issue in May 2026.
- The Board approved the unaudited financial results and confirmed the trading window opens from October 23, 2026.
- The company plans a preferential issue of 16,02,870 equity shares, awaiting in-principle approval from BSE Limited.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue From Operation (H1 FY27)
Rs. 489.20 Lacs
166.19
Profit Before Tax (H1 FY27)
Rs. 682.66 Lacs
187.31
Profit For the period (H1 FY27)
Rs. 507.66 Lacs
190.62
Basic EPS (H1 FY27)
Rs. 2.96
116.06
Total Equity and Liabilities (as of Sep 30, 2026)
Rs. 5,455.43 Lacs
🏢 How This Affects the Company
The company's revenue from operations increased to Rs. 489.20 Lacs for the half year ended September 30, 2026, indicating continued business activity. The proposed preferential issue of 16,02,870 equity shares suggests an intent to raise capital for business expansion or other corporate purposes.
Net Profit for the half year ended September 30, 2026, was Rs. 507.66 Lacs, a substantial increase from Rs. 174.69 Lacs in the prior comparable period. Equity Share Capital increased to Rs. 1,715.00 Lacs as of September 30, 2026, from Rs. 686.00 Lacs on March 31, 2026, primarily due to the bonus issue. Long-term borrowings increased to Rs. 704.27 Lacs from Rs. 52.16 Lacs.
Not directly detailed in the financial results, however, the increase in Inventories to Rs. 1,625.30 Lacs and Trade Receivables to Rs. 2,864.23 Lacs as of September 30, 2026, reflects increased operational scale.
The proposed preferential issue, while a capital raising measure, carries the risk of not receiving requisite regulatory and statutory approvals, as indicated by its pending status with BSE Limited. The significant increase in long-term borrowings could also represent an increased financial leverage risk.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on these financial results and proposed preferential issue, as it is pending approvals.
👤
Who Is Affected
Existing shareholders will be affected by the proposed preferential issue as it will dilute their ownership percentage if they do not participate or if the issue proceeds. The bonus issue in May 2026 already altered share capital.
🔍
Management Signal
The Board's approval of half-year results and the pursuit of a preferential issue indicate management's focus on capital raising and potential expansion to support growth.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of preferential issue approval from BSE Limited.
Allotment of 16,02,870 equity shares after regulatory approvals.
Next quarterly or half-yearly financial results to observe sustained performance.
MEDIUM RISK
Dependence on regulatory approvals for preferential issue and increased long-term borrowings present financial and execution risks.
💡 Investor Takeaway
Aptus Pharma Limited reported Net Profit of Rs. 507.66 Lacs for the half year ended September 30, 2026, an increase of 190.62% from Rs. 174.69 Lacs YoY. Revenue from Operations grew by 166.19% to Rs. 489.20 Lacs. The company also announced a preferential issue for 16,02,870 equity shares, pending regulatory approvals.
⚖️ Strengths & Concerns
✅ Positives
- Net Profit significantly increased to Rs. 507.66 Lacs for H1 FY27, up 190.62% YoY from Rs. 174.69 Lacs in H1 FY26.
- Revenue from Operations grew to Rs. 489.20 Lacs for H1 FY27, up 166.19% YoY from Rs. 183.75 Lacs in H1 FY26.
⚠️ Concerns
- Total Shareholder's Fund as of September 30, 2026, decreased to Rs. 2,842.27 Lacs from Rs. 2,334.62 Lacs as of March 31, 2026, which is inconsistent with the presented numbers.
- Long term borrowings increased substantially to Rs. 704.27 Lacs as of September 30, 2026, from Rs. 52.16 Lacs as of March 31, 2026.
📅 Company Track Record
Aptus Pharma's H1 FY27 PAT of Rs. 507.66 Lacs reflects a significant increase compared to H1 FY26 PAT of Rs. 174.69 Lacs. The company's revenue for H1 FY27 of Rs. 489.20 Lacs is up from H1 FY26 revenue of Rs. 183.75 Lacs. Previous full-year FY26 revenue was Rs. 4,670.81 Lakhs, with profit growth halving, warranting monitoring of margin compression.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Aptus Pharma's net profit for the half year ended September 30, 2026?
Aptus Pharma's net profit for the half year ended September 30, 2026, was Rs. 507.66 Lacs, an increase from Rs. 174.69 Lacs in the comparable prior period.
What was Aptus Pharma's revenue from operations for H1 FY27?
Aptus Pharma's Revenue from Operations for the half year ended September 30, 2026 (H1 FY27), was Rs. 489.20 Lacs, up from Rs. 183.75 Lacs in the prior comparable period.
What is the status of Aptus Pharma's proposed preferential issue?
Aptus Pharma's proposed preferential issue of 16,02,870 equity shares is awaiting in-principle approval from BSE Limited. The company has not yet received share application money or allotted shares for this issue.
How many bonus shares did Aptus Pharma issue in May 2026?
Aptus Pharma issued 102.90 lakh bonus equity shares in May 2026, in the ratio of 3:2, resulting in 171.50 lakh outstanding equity shares.
Questions based on this BSE filing only. For information purposes.